Key Highlights

  • Amylyx Pharmaceuticals shares are up 16% at $24.80 during extended hours.
  • The company is scheduled to disclose primary Phase 3 LUCIDITY data on August 18, 2026.
  • The trial evaluates avexitide for post-bariatric hypoglycemia.
  • Leadership will conduct a conference call and webcast at 8:00 AM ET to review the clinical findings.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares are up 16% at $24.80 during extended hours ahead of the company's scheduled disclosure of primary data from its Phase 3 LUCIDITY study evaluating avexitide for post-bariatric hypoglycemia on August 18, 2026.

What Happened

Following the announcement, Leadership will conduct a conference call and webcast at 8:00 AM ET to review the clinical findings.

Market Reaction

Shares rose in extended trading as investors positioned ahead of the scheduled data disclosure, reflecting anticipation heading into the readout for avexitide in post-bariatric hypoglycemia.

Outlook

The scheduled August 18, 2026 data disclosure and accompanying conference call represent the immediate next catalyst for Amylyx Pharmaceuticals' stock, with the actual trial results likely to be the primary driver of the stock's direction following the announcement.